Problems related to resistance to cytarabine in acute myeloid leukemia

Leukemia and Lymphoma

Volumn 45, Issue 6, 2004, Pages 1123-1132

  Cros, Emeline ^a   Jordheim, Lars ^a   Dumontet, Charles ^a   Galmarini, Carlos M ^a  

^a INSERM   (France)

Author keywords

Cytarabine; Drug resistance; Leukemia

Indexed keywords

5' NUCLEOTIDASE; ANTHRACYCLINE; CYTARABINE; CYTIDINE DEAMINASE; CYTIDINE PHOSPHATE; DNA; DNA POLYMERASE; DNA TOPOISOMERASE INHIBITOR; ENZYME INHIBITOR; ETOPOSIDE; FLUDARABINE; GEMCITABINE; HYDROXYUREA; NUCLEOTIDE DERIVATIVE; NUCLEOTIDE TRANSPORTER; PROTEIN KINASE; RIBONUCLEOTIDE REDUCTASE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CELL KINETICS; CYTOTOXICITY; DRUG METABOLISM; DRUG PENETRATION; DRUG RESPONSE; DRUG TRANSPORT; ENZYME DEFICIENCY; ENZYME INHIBITION; HUMAN; LEUKEMIA CELL; PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ACUTE DISEASE; ANTIMETABOLITES, ANTINEOPLASTIC; CYTARABINE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; LEUKEMIA, MYELOID; RIBONUCLEOTIDE REDUCTASES;

EID: 2342467325     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819032000159861     Document Type: Review

References (125)

1. Hiddemann, W. (1991) "Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens" , Ann. Hematol., 62, 119-128.
2. Rowe, J.M. (1998) "What is the best induction regimen for acute myelogenous leukemia?" Leukemia, 12(Suppl 1), S16-S19.
3. Burk, M., Heyll, A., Arning, M., Volmer, M., Fartash, K. and Schneider, W. (1997) "Pharmacokinetics of high-dose cytarabine and its deamination product - a reappraisal", Leuk. Lymphoma, 27, 321-327.
4. Del Poeta, G., Stasi, R., Aronica, G., Venditti, A., Cox, M.C., Bruno, A., Buccisano, F., et al. (1996) "Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia", Blood, 87, 1997-2004.
5. List, A.F., Spier, C.S., Grogan, T.M., Johnson, C., Roe, D.J., Greer, J.P., et al. (1996) "Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia", Blood, 87, 2464-2469.
6. Michieli, M., Damiani, D., Ermacora, A., Masolini, P., Raspadori, D., Visani, G., et al. (1999) "P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications", Br. J. Haematol., 104, 328-335.
7. van den Heuvel-Eibrink, M.M., Wiemer, E.A., Prins, A., Meijerink, J.P., Vossebeld, P.J., van der Holt, B., et al. (2002) "Increased expression of the breast cancer resistance protein (BCRP in relapsed or refractory acute myeloid leukemia (AML)", Leukemia, 16, 833-839.
8. Leith, C.P., Kopecky, K.J., Godwin, J., McConnell, T., Slovak, M.L., Chen, I.M., et al. (1997) "Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study", Blood, 89, 3323-3329.
9. Schuurhuis, G.J., Broxterman, H.J., Ossenkoppele, G.J., Baak, J.P., Eekman, C.A., Kuiper, C.M., et al. (1995) "Functional multidrug resistance phenotype associated with combined over-expression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia" , Clin. Cancer Res., 1, 81-93.
10. Kufe, D.W., Major, P.P., Egan, E.M. and Beardsley, G.P. (1980) "Correlation of cytotoxicity with incorporation of ara-C into DNA", J. Biol. Chem., 255, 8997-8900.
11. Plagemann, P.G., Marz, R. and Wohlhueter, R.M. (1978) "Transport and metabolism of deoxycytidine and 1-beta-D-arabinofuranosylcytosine into cultured Novikoff rat hepatoma cells, relationship to phosphorylation, and regulation of triphosphate synthesis", Cancer Res., 38, 978-989.
12. Wiley, J.S., Taupin, J., Jamieson, G.P., Snook, M., Sawyer, W.H. and Finch, L.R. (1985) "Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma", J. Clin. Invest., 75, 632-642.
13. Mackey, J., Baldwin, S.A., Young, J.D. and Cass, C.E. (1998) "Nucleoside transport and its significance for anticancer drug resistance", Drug Resistance Updates, 1, 310-324.
14. Mackey, J.R., Mani, R.S., Selner, M., Mowles, D., Young, J.D., Belt, J.A., et al. (1998) "Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines", Cancer Res., 58, 4349-4357.
15. Boleti, H., Coe, I.R., Baldwin, S.A., Young, J.D. and Cass, C.E. (1997) "Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells", Neuropharmacology, 36, 1167-1179.
16. Coleman, C.N., Stoller, R.G., Drake, J.C. and Chabner, B.A. (1975) "Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes", Blood, 46, 791-803.
17. Van Rompay, A.R., Johansson, M. and Karlsson, A. (1999) "Phosphorylation of deoxycytidine analog monophosphates by UMP-CMP kinase: molecular characterization of the human enzyme", Mol. Pharmacol., 56, 562-569.
18. Schneider, B., Xu, Y.W., Janin, J., Veron, M. and Deville-Bonne, D. (1998) "3′-Phosphorylated nucleotides are tight binding inhibitors of nucleoside diphosphate kinase activity" , J. Biol. Chem., 273, 28773-28778.
19. Laliberte, J. and Momparler, R.L. (1994) "Human cytidine deaminase: purification of enzyme, cloning, and expression of its complementary DNA", Cancer Res., 54, 5401-5407.
20. Galmarini, C.M., Mackey, J.R. and Dumontet, C. (2001) "Nucleoside analogues: mechanisms of drug resistance and reversal strategies", Leukemia, 15, 875-890.
21. Major, P.P., Egan, E.M., Beardsley, G.P., Minden, M.D. and Kufe, D.W. (1981) "Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA", Proc. Natl. Acad. Sci. USA, 78, 3235-3239.
22. Major, P.P., Egan, E.M., Herrick, D.J. and Kufe, D.W. (1982) "Effect of ARA-C incorporation on deoxyribonucleic acid synthesis in cells", Biochem. Pharmacol., 31, 2937-2940.
23. Gunji, H., Kharbanda, S. and Kufe, D. (1991) "Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells by 1-beta-D-arabinofuranosylcytosine", Cancer Res., 51, 741-743.
24. Raza, A., Gezer, S., Anderson, J., Lykins, J., Bennett, J., Browman, G., et al. (1992) "Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup study", Exp. Hematol., 20, 1194-1200.
25. Estey, E., Plunkett, W., Dixon, D., Keating, M., McCredie, K. and Freireich, E.J. (1987) "Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia", Leukemia, 1, 580-583.
26. White, J.C., Rathmell, J.P. and Capizzi, R.L. (1987) "Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells", J. Clin. Invest., 79, 380-387.
27. Gati, W.P., Paterson, A.R., Larratt, L.M., Turner, A.R. and Belch, A.R. (1997) "Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein", Blood, 90, 346-353.
28. Gati, W.P., Paterson, A.R., Belch, A.R., Chlumecky, V., Larratt, L.M., Mant, M.J., et al. (1998) "Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC)", Leuk. Lymphoma, 32, 45-54.
29. Baldwin, S.A., Mackey, J.R., Cass, C.E. and Young, J.D. (1999) "Nucleoside transporters: molecular biology and implications for therapeutic development", Mol. Med. Today, 5, 216-224.
30. Galmarini, C.M., Thomas, X., Calvo, F., Rousselot, P., Jafaari, A.E., Cros, E., et al. (2002) "Potential mechanisms of resistance to cytarabine in AML patients", Leuk. Res., 26, 621-629.
31. Wiley, J.S., Jones, S.P., Sawyer, W.H. and Paterson, A.R. (1982) "Cytosine arabinoside influx and nucleoside transport sites in acute leukemia", J. Clin. Invest., 69, 479-489.
32. Galmarini, C.M., Thomas, X., Calvo, F., Rousselot, P., Rabilloud, M., El Jaffari, A., et al. (2002) "In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia", Br. J. Haematol., 117, 860-868.
33. Arner, E.S. and Eriksson, S. (1995) "Mammalian deoxyribonucleoside kinases", Pharmacol. Ther., 67, 155-186.
34. Verhoef, V., Sarup, J. and Fridland, A. (1981) "Identification of the mechanism of activation of 9-beta-D-arabinofuranosyladenine in human lymphoid cells using mutants deficient in nucleoside kinases", Cancer Res., 41, 4478-4483.
35. Bhalla, K., Nayak, R. and Grant, S. (1984) "Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D-arabinofuranosylcytosine", Cancer Res., 44, 5029-5037.
36. Stegmann, A.P., Honders, M.W., Kester, M.G., Landegent, J.E. and Willemze, R. (1993) "Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2′-deoxycytidine", Leukemia, 7, 1005-1011.
37. Dumontet, C., Fabianowska-Majewska, K., Mantincic, D., Callet Bauchu, E., Tigaud, I., Gandhi, V., et al. (1999) "Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562", Br. J. Haematol., 106, 78-85.
38. Stegmann, A.P., Honders, W.H., Willemze, R., Ruiz van Haperen, V.W. and Landegent, J.E. (1995) "Transfection of wild-type deoxycytidine kinase (dck) cDNA into an AraC- and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity" , Blood, 85, 1188-1194.
39. Hapke, D.M., Stegmann, A.P. and Mitchell, B.S. (1996) "Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity", Cancer Res., 56, 2343-2347.
40. Orr, R.M., Talbot, D.C., Aherne, W.G., Fisher, T.C., Serafinowski, P. and Harrap, K.R. (1995) "2′-Deoxycytidine kinase deficiency is a major determinant of 2-chloro-2′ -deoxyadenosine resistance in lymphoid cell lines", Clin. Cancer Res., 1, 391-398.
41. Owens, J.K., Shewach, D.S., Ullman, B. and Mitchell, B.S. (1992) "Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene", Cancer Res., 52, 2389-2393.
42. Kakihara, T., Fukuda, T., Tanaka, A., Emura, I., Kishi, K., Asami, K., et al. (1998) "Expression of deoxycytidine kinase (dCK) gene in leukemic cells in childhood: decreased expression of dCK gene in relapsed leukemia", Leuk. Lymphoma, 31, 405-409.
43. Stammler, G., Zintl, F., Sauerbrey, A. and Volm, M. (1997) "Deoxycytidine kinase mRNA expression in childhood acute lymphoblastic leukemia", Anticancer Drugs, 8, 517-521.
44. Flasshove, M., Strumberg, D., Ayscue, L., Mitchell, B.S., Tirier, C., Heit, W., et al. (1994) "Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside", Leukemia, 8, 780-785.
45. Veuger, M.J., Honders, M.W., Landegent, J.E., Willemze, R. and Barge, R.M. (2000) "High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia", Blood, 96, 1517-1524.
46. Chiba, P., Tihan, T., Szekeres, T., Salamon, J., Kraupp, M., Eher, R., et al. (1990) "Concordant changes of pyrimidine metabolism in blasts of two cases of acute myeloid leukemia after repeated treatment with ara-C in vivo", Leukemia, 4, 761-765.
47. Chottiner, E.G., Shewach, D.S., Datta, N.S., Ashcraft, E., Gribbin, D., Ginsburg, D., et al. (1991) "Cloning and expression of human deoxycytidine kinase cDNA", Proc. Natl. Acad Sci. USA, 88, 1531-1535.
48. Harris, A.L., Grahame-Smith, D.G., Potter, C.G. and Bunch, C. (1981) "Cytosine arabinoside deamination in human leukaemic myeloblasts and resistance to cytosine arabinoside therapy", Clin. Sci. (Lond), 60, 191-198.
49. Jahns-Streubel, G., Reuter, C., Auf der Landwehr, U., Unterhalt, M., Schleyer, E., Wormann, B., et al. (1997) "Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia", Blood, 90, 1968-1976.
50. Jahns-Streubel, G., Reuter, C., Unterhalt, M., Schleyer, E., Wormann, B., Buchner, T., et al. (1995) "Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia", Leukemia, 9, 1857-1863.
51. Colly, L.P., Peters, W.G., Richel, D., Arentsen-Honders, M.W., Starrenburg, C.W. and Willemze, R. (1987) "Deoxycytidine kinase and deoxycytidine deaminase values correspond closely to clinical response to cytosine arabinoside remission induction therapy in patients with acute myelogenous leukemia", Semin. Oncol., 14, 257-261.
52. Tattersall, M.H., Ganeshaguru, K. and Hoffbrand, A.V. (1974) "Mechanisms of resistance of human acute leukaemia cells to cytosine arabinoside", Br. J. Haematol., 27, 39-46.
53. Galmarini, C.M., Thomas, X., Graham, K., El Jafaari, A., Cros, E., Jordheim, L., et al. (2003) "Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine", Br. J. Haematol., 122, 53-60.
54. Taub, J.W., Matherly, L.H., Stout, M.L., Buck, S.A., Gurney, J.G. and Ravindranath, Y. (1996) "Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia", Blood, 87, 3395-3403.
55. Taub, J.W., Huang, X., Matherly, L.H., Stout, M.L., Buck, S.A., Massey, G.V., et al. (1999) "Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin", Blood, 94, 1393-1400.
56. Taub, J.W., Huang, X., Ge, Y., Dutcher, J.A., Stout, M.L., Mohammad, R.M., et al. (2000) "Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome", Cancer Res., 60, 6421-6426.
57. Galmarini, C.M., Jordheim, L. and Dumontet, C. (2003) "Role of IMP-selective 5′-nucleotidase (cN-II) in hematological malignancies", Leuk. Lymphoma, 44, 1105-1111.
58. Boyle, J.M., Hey, Y., Guerts van Kessel, A. and Fox, M. (1988) "Assignment of ecto-5′-nucleotidase to human chromosome 6", Hum. Genet., 81, 88-92.
59. Resta, R., Hooker, S.W., Hansen, K.R., Laurent, A.B., Park, J.L., Blackburn, M.R., et al. (1993) "Murine ecto-5′ -nucleotidase (CD73): cDNA cloning and tissue distribution", Gene, 133, 171-177.
60. Resta, R., Yamashita, Y. and Thompson, L.F. (1998) "Ectoenzyme and signaling functions of lymphocyte CD73", Immunol. Rev., 161, 95-109.
61. Skladanowski, A.C., Smolenski, R.T., Tavenier, M., de Jong, J.W., Yacoub, M.H. and Seymour, A.M. (1996) "Soluble forms of 5′-nucleotidase in rat and human heart", Am. J. Physiol., 270, H1493-H1500.
62. Hunsucker, S.A., Spychala, J. and Mitchell, B.S. (2001) "Human cytosolic 5′-nucleotidase I: characterization and role in nucleoside analog resistance", J. Biol. Chem., 276, 10498-10504.
63. Sala-Newby, G.B., Skladanowski, A.C. and Newby, A.C. (1999) "The mechanism of adenosine formation in cells. Cloning of cytosolic 5′-nucleotidase-I", J. Biol. Chem., 274, 17789-17793.
64. Spychala, J., Madrid-Marina, V. and Fox, I.H. (1989) "Evidence for "low Km" and "high Km" soluble 5′-nucleotidases in human tissues and rat liver", Adv. Exp. Med. Biol., 253B, 129-134.
65. Itoh, R. (1993) "IMP-GMP 5′-nucleotidase", Comp. Biochem. Physiol. B, 105, 13-19.
66. Rampazzo, C., Johansson, M., Gallinaro, L., Ferraro, P., Hellman, U., Karlsson, A., et al. (2000) "Mammalian 5′(3′)-deoxyribonucleotidase, cDNA cloning, and overexpression of the enzyme in Escherichia coli and mammalian cells", J. Biol. Chem., 275, 5409-5415.
67. Amici, A. and Magni, G. (2002) "Human erythrocyte pyrimidine 5′-nucleotidase, PN-I", Arch. Biochem. Biophys., 397, 184-190.
68. Amici, A., Emanuelli, M., Raffaelli, N., Ruggieri, S. and Magni, G. (1999) "Pyrimidine nucleotidases/phosphotransferases from human erythrocyte", Nucleosides Nucleotides, 18, 853-855.
69. Rampazzo, C., Gallinaro, L., Milanesi, E., Frigimelica, E., Reichard, P. and Bianchi, V. (2000) "A deoxyribonucleotidase in mitochondria: involvement in regulation of dNTP pools and possible link to genetic disease", Proc. Natl. Acad. Sci. USA, 97, 8239-8244.
70. Schirmer, M., Stegmann, A.P., Geisen, F. and Konwalinka, G. (1998) "Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5′-nucleotidase activity", Exp. Hematol., 26, 1223-1228.
71. Mazzon, C., Rampazzo, C., Scaini, M.C., Gallinaro, L., Karlsson, A., Meier, C., et al. (2003) "Cytosolic and mitochondrial deoxyribonucleotidases: activity with substrate analogs, inhibitors and implications for therapy", Biochem. Pharmacol., 66, 471-479.
72. Galmarini, C.M., Graham, K., Thomas, X., Calvo, F., Rousselot, P., El Jafaari, A., et al. (2001) "Expression of high Km 5′-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia", Blood, 98, 1922-1926.
73. Capizzi, R.L., White, J.C., Powell, B.L. and Perrino, F. (1991) "Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine", Semin. Hematol., 28, 54-69.
74. Honma, Y., Onozuka, Y., Okabe-Kado, J., Kasukabe, T. and Hozumi, M. (1991) "Hemin enhances the sensitivity of erythroleukemia cells to 1-beta-D-arabinofuranosylcytosine by both activation of deoxycytidine kinase and reduction of cytidine deaminase activity", Cancer Res., 51, 4535-4538.
75. Momparler, R.L. and Laliberte, J. (1990) "Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2′-deoxycytidine", Leuk. Res., 14, 751-754.
76. Momparler, R.L., Eliopoulos, N., Bovenzi, V., Letourneau, S., Greenbaum, M. and Cournoyer, D. (1996) "Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblast and hematopoietic cells", Cancer Gene Ther., 3, 331-338.
77. Schroder, J.K., Kirch, C., Flasshove, M., Kalweit, H., Seidelmann, M., Hilger, R., et al. (1996) "Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro", Leukemia, 10, 1919-1924.
78. Neff, T. and Blau, C.A. (1996) "Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine", Exp. Hematol., 24, 1340-1346.
79. Steuart, C.D. and Burke, P.J. (1971) "Cytidine deaminase and the development of resistance to arabirosyl cytosine", Nat. New Biol., 233, 109-110.
80. Kirch, H.C., Schroder, J., Hoppe, H., Esche, H., Seeber, S. and Schutte, J. (1998) "Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro", Exp. Hematol., 26, 421-425.
81. Schroder, J.K., Kirch, C., Seeber, S. and Schutte, J. (1998) "Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia", Br. J. Haematol., 103, 1096-1103.
82. Chabner, B.A., Hande, K.R. and Drake, J.C. (1979) "Ara-C metabolism: implications for drug resistance and drug interactions", Bull. Cancer, 66, 89-92.
83. Liliemark, J.O. and Plunkett, W. (1986) "Regulation of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate accumulation in human leukemia cells by deoxycytidine 5′-triphosphate", Cancer Res., 46, 1079-1083.
84. Kunz, B.A. (1988) "Mutagenesis and deoxyribonucleotide pool imbalance", Murat. Res., 200, 133-147.
85. Meuth, M. (1989) "The molecular basis of mutations induced by deoxyribonucleoside triphosphate pool imbalances in mammalian cells", Exp. Cell Res., 181, 305-316.
86. Ohno, Y., Spriggs, D., Matsukage, A., Ohno, T. and Kufe, D. (1988) "Effects of 1-beta-D-arabinofuranosylcytosine incorporation on elongation of specific DNA sequences by DNA polymerase beta", Cancer Res., 48, 1494-1498.
87. Fritzer-Szekeres, M., Salamon, A., Grusch, M., Horvath, Z., Hochtl, T., Steinbrugger, R., et al. (2002) "Trimidox, an inhibitor of ribonucleotide reductase, synergistically enhances the inhibition of colony formation by Ara-C in HL-60 human promyelocytic leukemia cells", Biochem. Pharmacol., 64, 481-485.
88. Verschuur, A.C., Van Gennip, A.H., Leen, R., Voute, P.A., Brinkman, J. and Van Kuilenburg, A.B. (2002) "Cyclopentenyl cytosine increases the phosphorylation and incorporation into DNA of 1-beta-D-arabinofuranosyl cytosine in a human T-lymphoblastic cell line", Int. J. Cancer, 98, 616-623.
89. Yoshida, S., Yamada, M. and Masaki, S. (1977) "Inhibition of DNA polymerase-alpha and -beta of calf thymus by 1-beta-D-arabinofuranosylcytosine-5′-triphosphate", Biochim. Biophys. Acta, 477, 144-150.
90. Wills, P.W., Hickey, R. and Malkas, L. (2000) "Ara-C differentially affects multiprotein forms of human cell DNA polymerase", Cancer Chemother. Pharmacol., 46, 193-203.
91. Harrington, C. and Perrino, F.W. (1995) "The effects of cytosine arabinoside on RNA-primed DNA synthesis by DNA polymerase alpha-primase", J. Biol. Chem., 270, 26664-26669.
92. Perrino, F.W. and Mekosh, H.L. (1992) "Incorporation of cytosine arabinoside monophosphate into DNA at internucleotide linkages by human DNA polymerase alpha", J. Biol. Chem., 267, 23043-23051.
93. Tanaka, M. and Yoshida, S. (1982) "Altered sensitivity to 1-beta-D-arabinofuranosylcytosine 5′-triphosphate of DNA polymerase alpha from leukemic blasts of acute lymphoblastic leukemia", Cancer Res., 42, 649-653.
94. Higashigawa, M., Ido, M., Nagao, Y., Kuwabara, H., Hori, H., Ohkubo, T., et al. (1991) "Decreased DNA polymerase sensitivity to 1-beta-D-arabinofuranosylcytosine 5′-triphosphate in P388 murine leukemic cells resistant to vincristine", Leuk. Res., 15, 675-681.
95. Ross, D.D., Thompson, B.W., Joneckis, C.C., Akman, S.A. and Schiffer, C.A. (1986) "Metabolism of ara-C by blast cells from patients with ANLL", Blood, 68, 76-82.
96. Ho, Y.K., Reddy, A.R., Aradi, J., Minowada, J. and Bardos, T.J. (1985) "Inhibition of DNA polymerase alpha from leukemic and normal human cells by partially thiolated human deoxyribonucleic acids", Cancer Biochem. Biophys., 8, 85-94.
97. Wang, J.C. (1991) "DNA topoisomerases: why so many?" J. Biol. Chem., 266, 6659-6662.
98. Martincic, D., Kravtsov, V., Whitlock, J.A. and Dumontet, C. (1999) "Sensitivity of HEL and K562 cell lines to topotecan correlates with the level of topoisomerase I expression activity", Proc. Am. Assoc. Cancer Res., 40, A719.
99. Goz, B. and Bastow, K.F. (1997) "A possible role for topoisomerase II in cell death and N-phosphonoacetyl-L-aspartate-resistance frequency and its enhancement by 1-beta-D-arabinofuranosyl cytosine and 5-fluoro-2′ -deoxyuridine", Mutat. Res., 384, 89-106.
100. Cline, S.D. and Osheroff, N. (1999) "Cytosine arabinoside lesions are position-specific topoisomerase II poisons and stimulate DNA cleavage mediated by the human type II enzymes", J. Biol. Chem., 274, 29740-29743.
101. Kaufmann, S.H., Karp, J.E., Jones, R.J., Miller, C.B., Schneider, E., Zwelling, L.A., et al. (1994) "Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia", Blood, 83, 517-530.
102. Lohri, A., van Hille, B., Bacchi, M., Fopp, M., Joncourt, F., Reuter, J., et al. (1997) "Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bcl-2 and topoisomerase IIalpha) in 57 newly diagnosed acute myeloid leukaemias. Swiss Group for Clinical Cancer Research (SAKK)", Eur. J. Haematol., 59, 206-215.
103. Plunkett, W., Iacoboni, S., Estey, E., Danhauser, L., Liliemark, J.O. and Keating, M.J. (1985) "Pharmacologically directed ara-C therapy for refractory leukemia", Semin. Oncol., 12, 20-30.
104. Spasokoukotskaja, T., Sasvari-Szekely, M., Keszler, G., Albertioni, F., Eriksson, S. and Staub, M. (1999) "Treatment of normal and malignant cells with nucleoside analogues and etoposide enhances deoxycytidine kinase activity", Eur. J. Cancer, 35, 1862-1867.
105. Spasokoukotskaja, T., Sasvari-Szekely, M., Hullan, L., Albertioni, F., Eriksson, S. and Staub, M. (1998) "Activation of deoxycytidine kinase by various nucleoside analogues", Adv. Exp. Med. Biol., 431, 641-645.
106. Csapo, Z., Keszler, G., Safrany, G., Spasokoukotskaja, T., Talianidis, I., Staub, M., et al. (2003) "Activation of deoxycytidine kinase by gamma-irradiation and inactivation by hyperosmotic shock in human lymphocytes", Biochem. Pharmacol., 65, 2031-2039.
107. Van Den Neste, E., Smal, C., Cardoen, S., Delacauw, A., Frankard, J., Ferrant, A., et al. (2003) "Activation of deoxycytidine kinase by UV-C-irradiation in chronic lymphocytic leukemia B-lymphocytes", Biochem. Pharmacol., 65, 573-580.
108. Galmarini, C.M., Mackey, J.R. and Dumontet, C. (2002) "Nucleoside analogues and nucleobases in cancer treatment", Lancet Oncol., 3, 415-424.
109. Galmarini, C.M., Clarke, M.L., Santos, C.L., Jordheim, L., Perigaud, C., Gosselin, G., et al. (2003) "Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue", International Journal of Cancer, 107, 149-154.
110. Schlienger, N., Peyrottes, S., Kassem, T., Imbach, J.L., Gosselin, G., Aubertin, A.M. and Perigaud, C. (2000) " S-Acyl-2-thioethyl aryl phosphotriester derivatives as mononucleotide prodrugs", J. Med. Chem., 43, 4570-4574.
111. Beltran, T., Egron, D., Pompon, A., Lefebvre, I., Perigaud, C., Gosselin, G., et al. (2001) "Rational design of a new series of pronucleotide", Bioorg. Med. Chem. Lett., 11, 1775-1777.
112. Iwasaki, H., Huang, P., Keating, M.J. and Plunkett, W. (1997) "Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells", Blood, 90, 270-278.
113. Gandhi, V. and Plunkett, W. (1988) "Modulation of arabinosyl-nucleoside metabolism by arabinosylnucleotides in human leukemia cells", Cancer Res., 48, 329-334.
114. Gandhi, V., Kemena, A., Keating, M.J. and Plunkett, W. (1992) "Fludarabine infusion potentiates arabinosyleytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia", Cancer Res., 52, 897-903.
115. Suki, S., Kantarjian, H., Gandhi, V., Estey, E., O'Brien, S., Beran, M., et al. (1993) "Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia" , Cancer, 72, 2155-2160.
116. Gandhi, V., Nowak, B., Keating, M.J. and Plunkett, W. (1989) "Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy", Blood, 74, 2070-2075.
117. Gandhi, V., Estey, E., Keating, M.J. and Plunkett, W. (1993) "Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy", J. Clin. Oncol., 11, 116-124.
118. Gandhi, V., Robertson, L.E., Keating, M.J. and Plunkett, W. (1994) "Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology", Cancer Chemother. Pharmacol., 34, 30-36.
119. Seymour, J.F., Huang, P., Plunkett, W. and Gandhi, V. (1996) "Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule", Clin. Cancer Res., 2, 653-658.
120. Keating, M.J., Estey, E., O'Brien, S., Kantarjian, H., Robertson, L.E. and Plunkett, W. (1994) "Clinical experience with fludarabine in leukaemia", Drugs, 47(Suppl 6), 39-49.
121. Avramis, V.I., Wiersma, S., Krailo, M.D., Ramilo-Torno, L.V., Sharpe, A., Liu-Mares, W., et al. (1998) "Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group", Clin. Cancer Res., 4, 45-52.
122. Colly, L.P., Richel, D.J., Arentsen-Honders, M.W., Kester, M.G., ter Riet, P.M. and Willemze, R. (1992) "Increase in Ara-C sensitivity in Ara-C sensitive and -resistant leukemia by stimulation of the salvage and inhibition of the de novo pathway", Ann. Hematol., 65, 26-32.
123. Bhalla, K., Swerdlow, P. and Grant, S. (1991) "Effects of thymidine and hydroxyurea on the metabolism and cytotoxicity of 1-B-D arabinofuranosylcytosine in highly resistant human leukemia cells", Blood, 78, 2937-2944.
124. Gandhi, V., Estey, E., Keating, M.J. and Plunkett, W. (1993) "Biochemical modulation of arabinosylcytosine for therapy of leukemias", Leuk. Lymphoma, 10(Suppl), 109-114.
125. Gandhi, V., Estey, E., Keating, M.J., Chucrallah, A. and Plunkett, W. (1996) "Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions", Blood, 87, 256-264.